Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jones Pharma Inc.

Division of Pfizer Inc.
www.kingpharm.com

Latest From Jones Pharma Inc.

MedPointe's Private Dilemma

MedPointe was born via the leveraged buy-out of an old, private pharmaceutical company, Carter-Wallace. Accepting financial strictures was part of the deal; the company must remain profitable. This increases the challenge for the "founders," seasoned pharma execs intent on leveraging the infrastructure they overhauled, to created an in-licensing based marketing powerhouse. Beyond competing with bigger pharma marketers, management's challenge remains bringing in new assets affordably.
BioPharmaceutical

MedPointe and Opportunities in Specialty Pharma: Speed is Expensive

The notion of building up a new drug company with the unwanted, undersized products of ever-bigger Big Pharma is hardly new. But MedPointe, with its acquisition of Carter Wallace's medical products business, is aiming to build up a new firm faster and bigger than can be done simply by in-licensing.
BioPharmaceutical Medical Device

Q & A on Reverse Licensing

An increasing amount of funding appears to be going to start-ups that in-license compounds from pharma companies in agreements known as reverse licensings. Some of the key points in structuring such a deal are: 1) defining the "licensed compound"; ensuring access to data and people; freedom to develop the compound in an unencumbered manner; buyback rights ;constructing sensible economics; and controlling the intellectual property.
BioPharmaceutical Strategy

Deal Statistics Quarterly, Q3 2000

In Vivo presents the second installment of a new quarterly feature--a statistical review compiled from Windhover's Strategic Transactions Database of the deal activity within the pharmaceuticals, biotechnology, medical device and in vitro diagnostics industries.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Jones Medical
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Pfizer Inc.
  • Senior Management
  • Jefferson Gregory, Pres.
    Judith A Jones, EVP, Treas.
    Michael T Bramblett, EVP, Bus. Dev.
  • Contact Info
  • Jones Pharma Inc.
    Phone: (314) 576-6100
    1945 Craig Rd.
    P.O. Box 46903 St. Louis, MO 63146
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register